EULAR 2024 PsA Daily Topic Podcasts

Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria: OP0195 Sonelokimab IL 17 A/F nanobody inhibitorLB0005 Izokibep IL17A nanobody inhibitorPOS0803 Vunakizumab, another IL17A inhibitorOP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib JAK Inhibitors for New IndicationsDr. Janet Pope discusses new indications for JAK inhibitors, reporting from Eular 2024 in Vienna, Austria. PsA Treatment: is Earlier Better?Dr. Aurelie Najm discusses abstract OP0184, presented at Eular 2024 in Vienna, Austria. Transition from Psoriasis to PsA: Can we Prevent It?Dr. Aurelie Najm discusses abstract OP0010 presented at Eular 2024 in Vienna, Austria. Depression and Anxiety Associated with Inability to Achieve Remission in RA and PsADr. Aurelie Najm reports on abstract POS0946 presented at Eular 2024 in Vienna, Austria. PsA Switch or Cycle, the Eternal QuestionDr. Aurelie Najm reports on abstracts POS0278 and POS0266 presented at Eular 2024 in Vienna, Austria. Axial & Psoriatic DiseaseDr. Peter Nash at Eular 2024 in Vienna, Austria. Difficult to Treat Psoriatic ArthritisDr. Peter Nash reports at Eular 2024 in Vienna, Austria. Predictors of Treatment Response in Psoriatic ArthritisDr. Janet Pope reviews three abstracts presented at Eular 2024 in Vienna, Austria. Abstracts discussed: POS 0990POS 0992POS 0266 Prevention of Psoriatic ArthritisDr. Peter Nash sharing his perspectives on preventing psoriasis from turning into PsA at Eular 2024 in Vienna, Austria.